Analystreport

Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $60.00 price target on the stock.

Arrowhead Pharmaceuticals, Inc.  (ARWR) 
Last arrowhead pharmaceuticals, inc. earnings: 2/5 04:00 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.arrowheadpharma.com/investor-relations